openPR Logo
Press release

Histone Deacetylase Inhibitors Market 2022: Global Key Players - Celgene Corporation, Celleron Therapeutics Ltd, Eisai Co., Ltd., Novartis International AG and more

08-16-2022 12:20 PM CET | Health & Medicine

Press release from: Persistence Market Research

/ PR Agency: Persistence Market Research
Histone Deacetylase Inhibitors Market 2022

Histone Deacetylase Inhibitors Market 2022

Histone Deacetylase Inhibitors Market 2022

Histone deacetylase (HDAC) is enzymes, which inhibits histone deacetylase by removing scetyl group from n-acetyl lysine amino acid. Histone deacetylase inhibitors are emerging as potential application in diagnosis, treatment and prognosis of cancer.  It is also considered as a treatment option for hematological malignancies and plays important role in epigenetic or non-epigenetic regulation.

Get Free Sample Copy Of This Report @ https://www.persistencemarketresearch.com/samples/14407

The histone deacetylase inhibitors accumulates acetylated nuclear histone in tumors and normal tissues. Thus, the inhabitation results in acetylation transcription factors such as GATA-1, p53 and estrogen receptor-alpha. These enzymes are found in fungi, bacteria, animals and plants. There are around 18 human histone deacetylase known, which are classified into four classes based on their structures. Class I HDAC1, HDAC2, HDAC3, and HDAC8. Class II includes HDAC4, HDAC5, HDAC7, and HDAC9.  Class III includes HDAC6 and HDAC10, whereas Class IV includes HDAC11.

The demand for histone deacetylase inhibitors is rapidly increasing owing to growing need for innovative therapies for cancer treatment. Histone deacetylase inhibitors plays vital role in regulation of gene expression via the effects on the chromatin structure.  Over the past few years, numerous histone deacetylase inhibitors molecules have undergone clinical trials for different types of cancer. These inhibitors are categorized based on their chemical structure. Among these categories hydroxamic acid-based compounds are the most widely explored class of histone deacetylase inhibitor.

Histone deacetylase inhibitors market has been segmented on the basis of class, application, end user and geography.

Based on the class, the histone deacetylase inhibitors market is segmented into the following:

Class I HDACs
Class II HDACs
Class III HDACs
Class IV HDACs

Based on the application, the histone deacetylase inhibitors market is segmented into the following:

Oncology
Neurology
Others

Based on the end user, the histone deacetylase inhibitors market is segmented into the following:

Hospitals
Oncology Clinics
Others

Based on application, the market is categorized into oncology, neurology, and other disease. Oncology is expected to be the leading segment owing to the large patient base and increasing need for novel therapies for the treatment of cancer patients. Currently, FDA have approved four products namely, Romidepsin (Istodax), orinostat (Zolinza), Vidaza and Dacogen. However, pharmaceutical companies are now heavily investing into research and development activities and preclinical activities of histone deacetylase inhibitors for different applications.

Based on the end user segment, the histone deacetylase inhibitors market is categories into hospitals, oncology clinics and other end users. Oncology clinics end user segment is expected to be the highest revenue generating segment owing to the increasing adoption of novel therapies for cancer treatment and increasing incidence of cancer across the globe.  Similarly, growing expenditure on R&D activities by pharmaceutical companies and increasing government funding for such activities is expected to drive the growth for the histone deacetylase inhibitors market during the forecast period.

Request to Browse Full Table of Content, figure and Tables @ https://www.persistencemarketresearch.com/toc/14407

Global histone deacetylase inhibitors market is experiencing significant growth owing to the increase incidence of different types of cancer and growing need for effective cancer diagnosis and therapeutics. Moreover, increasing R&D activities for the cancer treatment and other neurological disorders is one of the prime factor responsible for the market growth. However, unfavorable reimbursement policies and uncertainty issues of HDAC inhibitors might hamper the market growth to some extent.

Geographically Histone deacetylase inhibitors market is classified into regions viz. North America, Latin America, Europe, Asia-Pacific, Middle East and Africa. North America and Europe will remain key markets for Histone deacetylase inhibitors market due to presence of sophisticated healthcare infrastructure, high R&D spending capacity and early adoption of innovative therapeutics. Asia Pacific is anticipated to register positive growth owing to rising government's initiatives in healthcare sector, improved healthcare infrastructure and increasing cancer patients population in the region.

Some of the key players in the histone deacetylase inhibitors  market are Celgene Corporation, Celleron Therapeutics Ltd, Eisai Co., Ltd., Novartis International AG, Acetylon Pharmaceuticals, Inc.,  AstraZeneca plc., Merck & Co., Inc. Pfizer Inc. to name a few.

The report covers exhaustive analysis on:

Histone Deacetylase Inhibitors Market Segments
Histone Deacetylase Inhibitors Market Dynamics
Histone Deacetylase Inhibitors Market Size, 2016 - 2024
Histone Deacetylase Inhibitors Market Size & Forecast 2016 to 2024
Histone Deacetylase Inhibitors Market Current Trends/Issues/Challenges
Competition & Companies involved
Histone Deacetylase Inhibitors Market Drivers and Restraints

Key geographies evaluated in this report are:
North America - U.S, Canada
Europe - France, Germany, Italy, Spain, and the UK, Eastern Europe, CIS
APAC - China, India, Japan, Australia, Others
Latin America - Argentina, Brazil, Others

Buy Now@https://www.persistencemarketresearch.com/checkout/14407

Key Questions Answered in This Report.

What will the Market growth rate in Future?
What are the key factors driving the global Market?
Who are the key manufacturers in Market space?
What are the opportunities and threats faced by the vendors in the global industry?
What are sales, revenue, and price analysis by regions of industry?

Contact us:

Persistence Market Research          
Address - 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About us: 

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Histone Deacetylase Inhibitors Market 2022: Global Key Players - Celgene Corporation, Celleron Therapeutics Ltd, Eisai Co., Ltd., Novartis International AG and more here

News-ID: 2705655 • Views:

More Releases from Persistence Market Research

North America Wiring Devices Market Projected to Reach USD 26.46 Billion by 2031
North America Wiring Devices Market Projected to Reach USD 26.46 Billion by 2031
Overview of the North America Wiring Devices Market The North America wiring devices market is poised for steady growth over the forecast period, with its size estimated at US$ 18.96 billion in 2024, projected to reach US$ 26.46 billion by 2031, reflecting a CAGR of 4.9%. The market is witnessing substantial expansion due to increasing urbanization, a rising number of residential and commercial construction projects, and the adoption of energy-efficient and
Global Forged Automotive Components Market Poised for Steady Growth, Projected to Reach US$ 70.7 Billion by 2032
Global Forged Automotive Components Market Poised for Steady Growth, Projected t …
The global forged automotive components market is on a robust growth trajectory, currently valued at approximately US$ 50.3 billion in 2025 and forecasted to expand to US$ 70.7 billion by the end of 2032. This growth represents a compound annual growth rate (CAGR) of 5.0% over the coming decade, driven by increasing automotive production, technological advancements, and evolving consumer preferences toward durable, high-performance vehicle parts. Forged automotive components are critical to
Global Electric Cargo Bike Market Set to Accelerate at 11.9% CAGR, Reaching US$ 2.14 Billion by 2032, Reports Persistence Market Research
Global Electric Cargo Bike Market Set to Accelerate at 11.9% CAGR, Reaching US$ …
The global electric cargo bike market is set to experience substantial growth over the coming decade, with Persistence Market Research (PMR) forecasting a compound annual growth rate (CAGR) of 11.9% from 2023 through 2032. Valued at approximately US$ 800 million in 2021, the market is expected to surge to a projected valuation of US$ 2.14 billion by the end of 2032. Notably, electric cargo bikes accounted for 66.2% of the
Bicycle Bearings Market Set for Steady Growth with 6.5% CAGR Through 2032, Driven by Urbanization and Demographic Trends
Bicycle Bearings Market Set for Steady Growth with 6.5% CAGR Through 2032, Drive …
The global bicycle bearings market is poised for significant expansion over the forecast period of 2025 to 2032, according to the latest report released by Persistence Market Research. Valued at approximately US$ 5.99 billion in 2024, the market is projected to reach US$ 6.35 billion by 2025 and further escalate to nearly US$ 9.86 billion by 2032. This growth trajectory reflects a compound annual growth rate (CAGR) of 6.5%, underscoring

All 5 Releases


More Releases for Histone

Histone Deacetylase (HDAC) Inhibitors Market 2022 | Detailed Report
The Histone Deacetylase (HDAC) Inhibitors research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market's key players. Furthermore, the report offers insightful market data and information about the
Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Marke …
The Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Market report offers an in-depth assessment of market dynamics, the competitive landscape, segments, and regions in order to help readers to become familiar with the Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) market. It particularly sheds light on market fluctuations, pricing structure, uncertainties, potential risks, and growth prospects to help players to
Global Histone Deacetylase Inhibitors Market Research Report
This report studies the global Histone Deacetylase Inhibitors market status and forecast, categorizes the global Histone Deacetylase Inhibitors market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report 4SC AG Acetylon Pharmaceuticals Celleron Therapeutics Chroma Therapeutics CrystalGenomics Curis MEI Pharma Mirati Therapeutics Novartis
Histone Deacetylase Inhibitors Market & Pipeline Insight2015
Histone Deacetylase (HDAC) are enzymes responsible for removal of acetyl groups present on acetyl lysine amino acid attached to histone. They are responsible for gene expression and regulation which is responsible for cellular functioning. It also helps in wrapping of histone over the Deoxyribonucleic acid (DNA). They are involved in cell growth and death which is responsible for maintaining steady state. Their involvement in diseases has been noted by investigators
Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) - Pipeline …
The latest report Histone Deacetylase 4 - Pipeline Review, H1 2017, outlays comprehensive information on the Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviewsalso reviews key players involved in Histone Deacetylase 4 (Histone Deacetylase A or HDAC4 or EC 3.5.1.98) targeted therapeutics development
Global Histone Deacetylase Inhibitors Market
Histone deacetylase (HDAC) is enzymes, which inhibits histone deacetylase by removing scetyl group from n-acetyl lysine amino acid. Histone deacetylase inhibitors are emerging as potential application in diagnosis, treatment and prognosis of cancer. It is also considered as a treatment option for hematological malignancies and plays important role in epigenetic or non-epigenetic regulation. The histone deacetylase inhibitors accumulates acetylated nuclear histone in tumors and normal tissues. Thus, the inhabitation results